Geneva, December 20, 2021: Chord Therapeutics (Chord), a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, today announces that it is being acquired by ...
- Merck to accelerate development of Chord's innovative pipeline for generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD) - Focused expansion in neuroinflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results